Cargando…
A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial
PURPOSE: No consensus has currently been reached regarding the optimal radiation volume for radiotherapy of glioblastoma. Here, we have proposed a new delineation approach to delineating clinical target volume based on the relationship between the growth patterns of glioblastoma and neural pathways....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626993/ https://www.ncbi.nlm.nih.gov/pubmed/36338715 http://dx.doi.org/10.3389/fonc.2022.931436 |
_version_ | 1784822861396967424 |
---|---|
author | Huang, Yong Ding, Haixia Luo, Min Li, Zhiqiang Li, Sirui Xie, Conghua Zhong, Yahua |
author_facet | Huang, Yong Ding, Haixia Luo, Min Li, Zhiqiang Li, Sirui Xie, Conghua Zhong, Yahua |
author_sort | Huang, Yong |
collection | PubMed |
description | PURPOSE: No consensus has currently been reached regarding the optimal radiation volume for radiotherapy of glioblastoma. Here, we have proposed a new delineation approach to delineating clinical target volume based on the relationship between the growth patterns of glioblastoma and neural pathways. Its safety and efficacy were evaluated in a phase II clinical trial. METHODS: A total of 69 patients with histologically confirmed glioblastoma were enrolled. All patients underwent tumor resection, followed by focal radiotherapy and concomitant temozolomide (TMZ), and then received six cycles of adjuvant TMZ. The gross tumor volume (GTV) was defined as the surgical resection cavity plus any residual enhancing tumor, on contrast enhanced T1-weighted MRI. The clinical target volume (CTV) was delineated through our new approach. RESULTS: The median recurrence-free survival (RFS) and overall survival (OS) were 11.4 months and 18.2 months, which were better than the previous reports. Relapse was found in 47 patients, of whom 41 patients (87.2%) failed in central, two patients (4.3%) failed in field, and four patients (8.5%) failed in distance. No marginal recurrence was found. Our regimen showed a trend of lower rates of marginal recurrence, and the brain volume of high-dose radiation fields in our regimen was similar to that of EORTC (p = 0.257). CONCLUSIONS: We have proposed a novel method for the delineation of clinical target volume by referencing the nerve fiber bundles for radiotherapy of glioblastoma. The results of the present phase II clinical trial suggest that this approach may be feasible and effective. |
format | Online Article Text |
id | pubmed-9626993 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96269932022-11-03 A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial Huang, Yong Ding, Haixia Luo, Min Li, Zhiqiang Li, Sirui Xie, Conghua Zhong, Yahua Front Oncol Oncology PURPOSE: No consensus has currently been reached regarding the optimal radiation volume for radiotherapy of glioblastoma. Here, we have proposed a new delineation approach to delineating clinical target volume based on the relationship between the growth patterns of glioblastoma and neural pathways. Its safety and efficacy were evaluated in a phase II clinical trial. METHODS: A total of 69 patients with histologically confirmed glioblastoma were enrolled. All patients underwent tumor resection, followed by focal radiotherapy and concomitant temozolomide (TMZ), and then received six cycles of adjuvant TMZ. The gross tumor volume (GTV) was defined as the surgical resection cavity plus any residual enhancing tumor, on contrast enhanced T1-weighted MRI. The clinical target volume (CTV) was delineated through our new approach. RESULTS: The median recurrence-free survival (RFS) and overall survival (OS) were 11.4 months and 18.2 months, which were better than the previous reports. Relapse was found in 47 patients, of whom 41 patients (87.2%) failed in central, two patients (4.3%) failed in field, and four patients (8.5%) failed in distance. No marginal recurrence was found. Our regimen showed a trend of lower rates of marginal recurrence, and the brain volume of high-dose radiation fields in our regimen was similar to that of EORTC (p = 0.257). CONCLUSIONS: We have proposed a novel method for the delineation of clinical target volume by referencing the nerve fiber bundles for radiotherapy of glioblastoma. The results of the present phase II clinical trial suggest that this approach may be feasible and effective. Frontiers Media S.A. 2022-10-19 /pmc/articles/PMC9626993/ /pubmed/36338715 http://dx.doi.org/10.3389/fonc.2022.931436 Text en Copyright © 2022 Huang, Ding, Luo, Li, Li, Xie and Zhong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Huang, Yong Ding, Haixia Luo, Min Li, Zhiqiang Li, Sirui Xie, Conghua Zhong, Yahua A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial |
title | A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial |
title_full | A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial |
title_fullStr | A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial |
title_full_unstemmed | A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial |
title_short | A new approach to delineating clinical target volume for radiotherapy of glioblastoma: A phase II trial |
title_sort | new approach to delineating clinical target volume for radiotherapy of glioblastoma: a phase ii trial |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626993/ https://www.ncbi.nlm.nih.gov/pubmed/36338715 http://dx.doi.org/10.3389/fonc.2022.931436 |
work_keys_str_mv | AT huangyong anewapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT dinghaixia anewapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT luomin anewapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT lizhiqiang anewapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT lisirui anewapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT xieconghua anewapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT zhongyahua anewapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT huangyong newapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT dinghaixia newapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT luomin newapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT lizhiqiang newapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT lisirui newapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT xieconghua newapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial AT zhongyahua newapproachtodelineatingclinicaltargetvolumeforradiotherapyofglioblastomaaphaseiitrial |